Inside Oxeia Biopharma’s Mission to Heal Brain Damage From Concussions
Follow Inside Startup Investing wherever you listen.
On this episode of Inside Startup Investing, Chris Lustrino speaks with Dr. Michael Wyand, CEO of Oxeia Biopharma, a clinical-stage biotech company developing a potential breakthrough treatment for concussions and persistent concussion symptoms.
On this episode of Inside Startup Investing, Chris Lustrino speaks with Dr. Michael Wyand, CEO of Oxeia Biopharma, a clinical-stage biotech company developing a potential breakthrough treatment for concussions and persistent concussion symptoms.
Oxeia Biopharma
The company is pioneering a new approach to concussion treatment with its first-in-class ghrelin therapy. Oxeia Biopharma's OXE103 aims to deliver therapeutic doses of ghrelin immediately post-concussion and has demonstrated an 85% responder rate at the Phase 2a trial at the University of Kansas Medical Center. Enrollment for the Phase 2b trial is planned to begin in 2026 with 160 patients.
Oxeia is leveraging ghrelin, a naturally occurring hormone involved in brain energy regulation and neural repair, to help heal the inflammation and cellular damage caused by traumatic brain injuries. With promising Phase 2a data showing an 85% responder rate among treated patients, the company is pursuing what could become the first FDA-approved pharmaceutical treatment specifically targeting concussion recovery.
Chris and Michael discuss the science behind concussions, how brain damage occurs after impact, why “just rest” has remained the standard of care for decades, and how Oxeia’s therapy could fundamentally change the treatment landscape for athletes, veterans, and millions of patients suffering from lingering neurological symptoms.
They also dive into the company’s clinical pathway, the business opportunity behind concussion therapeutics, the role of neurogenesis in recovery, and the broader future potential for treating conditions like CTE, Parkinson’s disease, and ALS.
If you want to understand the future of concussion recovery, brain health innovation, and biotech investing, this is an episode you won’t want to miss.
Join the mission to bring the first FDA-approved treatment for persistent concussion symptoms to market.
Invest nowThis Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
